An HIV-derived nucleoside therapy now treats rare genetic diseases by restoring mitochondrial DNA and improving muscle ...
Gilead study finds HIV can evolve to resist lenacapavir, but doing so hampers the virus' replication
Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including ...
There’s been a lot of grim news lately about HIV and AIDS: Rising infections among high-risk U.S. communities, continued risk behaviors, and plague-level infection rates across sub-Saharan Africa. In ...
The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported Wednesday. In clinical trials, the drug nearly eliminated HIV’s spread among ...
Effect of the Initial Regimen on the Rate of Specific Mutations Even among different HAART regimens, the selection of the initial regimen also has important implications in terms of selecting for ...
2013 was a year of encouraging developments in treatments for HIV, the virus that causes AIDS. Although we still haven't found a cure for HIV, which affects approximately 34 million people worldwide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback